Aryl ureas as kinase inhibitors

US8110587B2 · kind B2 · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Jacques Dumas · Neuilly-Plaisance, FR
• William Scott · Guilford, US
• Bernd Riedl · Wuppertal, DE
• Du-Schieng Chien · Guilford, US
• Ala Nassar · Milford, US
• Wendy Lee · Hamden, US
• Susan Bjorge · Milford, US
• Laszlo L. Musza · New Haven, US

Key dates

• Filing date: Feb 11, 2003
• Grant date: Feb 7, 2012
• Expiry date: Feb 11, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D213/89
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.